Part B

DRUG5 trials

Sponsors

GlaxoSmithKline, AstraZeneca, TopAlliance Biosciences, Hutchison Medipharma Limited, Société des Produits Nestlé (SPN)

Conditions

Advanced MalignanciesArthritis, RheumatoidExocrine Pancreatic InsufficiencyGonococcal (GC) InfectionHealthy

Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914

CompletedNCT01929629

AstraZenecaGonococcal (GC) Infection

Start: 2013-09-30End: 2014-03-31Updated: 2014-04-15

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

CompletedNCT03474640

TopAlliance BiosciencesAdvanced Malignancies

Start: 2018-02-21End: 2022-07-07Updated: 2024-11-22

Surufatinib DDI With a PPI and a CYP3A Inducer

CompletedNCT04510649

Hutchison Medipharma LimitedHealthy

Start: 2020-07-09End: 2021-03-02Updated: 2021-06-18

Oral CDX-7108 in Healthy Adults and EPI Subjects

CompletedNCT05082051

Société des Produits Nestlé (SPN)Exocrine Pancreatic Insufficiency

Start: 2021-10-11End: 2023-03-16Updated: 2024-09-20

Phase 2

HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II

CompletedNCT00291928

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2005-02-28End: 2007-09-30Updated: 2012-11-12

Related Papers

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Journal of Immunotherapy and Precision Oncology2025-01-141 citations

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.

2018-12-2118 citations